Breaking News

Immunovative Upgrades Manufacturing Facility

Achieves milestone toward commercial cell-based GMP production

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Immunovative Therapies, Ltd. (ITL) has completed upgrades to its GMP cell manufacturing facility and GMP operations in Jerusalem to comply with the requirements of advanced clinical trials. The completion and validation of its manufacturing facility will allow the company to launch a Phase II/III trial as planned early in 2013.   The facility upgrades include: two class 10,000 cleanroom facilities, interlocked rooms with increasing levels of pressure and air quality, separate rooms for personnel...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters